Download presentation
Presentation is loading. Please wait.
Published byΆδωνις Βυζάντιος Modified over 6 years ago
1
Clinical Developments in Allergen Immunotherapy
3
Allergen Immunotherapy (AI) Overview
4
AI Overview (cont)
5
Recent Developments in AI
6
Cox et al Study of a 5-grass Pollen Sublingual Tablet
7
Primary Efficacy Data From 3 Studies of Grass Sublingual Tablet
8
Blaiss et al Study of Grass Pollen Sublingual Tablet
9
Blaiss et al Study of Grass Pollen Sublingual Tablet (cont)
10
Primary Efficacy Data From 2 Studies of Ragweed Sublingual Tablet
11
Ragweed Sublingual Tablet for AI
12
Reduction in TCS During Peak Ragweed Season
13
Where Sublingual AI Stands in the US
14
A Study of Sublingual Liquid AI
15
Results
16
Safety of Subcutaneous AI
17
Safety of Sublingual AI (cont)
18
Safety of Sublingual AI (cont)
19
Safety of Sublingual AI (cont)
20
Studies Directly Comparing SLIT and SCIT Adherencea
21
Monophosphoryl Lipid A (MPLA)
22
MPLA (cont)
23
Ultrashort-specific Immunotherapy for Seasonal Allergic Rhinoconjunctivitis Caused by Grass Pollen
24
Ultrashort-specific Immunotherapy (cont)
25
Abbreviations
26
References
27
References (cont)
28
References (cont)
29
References (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.